Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03616470 · ClinicalTrials.gov registry record · Phase 3
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
A Phase 3 study, sponsored by GlycoMimetics Incorporated.
- Terminated
- Registry status
- Phase 3
- Development phase
- 388
- Enrollment target
NCT03616470: Clinical Trial Phase 3 study, sponsored by GlycoMimetics Incorporated.
NCT03616470 is a Phase 3 study that was terminated before completion, run by GlycoMimetics Incorporated. The registered enrollment target is 388 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03616470, a Phase 3 study, was terminated before completion, sponsored by GlycoMimetics Incorporated.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 388 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML
Primary Outcome
Time from the date of randomization into the study to the date of death.
Interventions
- DRUG Placebo
- DRUG Uproleselan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 388 participants |
| Start Date | 2018-10-15 |
| Est. Completion | 2024-03-31 |
| Phase | Phase 3 |
Why NCT03616470 stopped before completion
NCT03616470 is an interventional study that assigns participants to a tested intervention. The registered 388 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03616470 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03616470 about?
NCT03616470 is a clinical study titled "Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia". This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with rela...
What is the current status of trial NCT03616470?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 388 participants. The study started on 2018-10-15. Estimated completion is 2024-03-31.
What interventions are being tested in trial NCT03616470?
The interventions under investigation include: Placebo (DRUG), Uproleselan (DRUG).
Who is sponsoring clinical trial NCT03616470?
This trial is sponsored by GlycoMimetics Incorporated, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03616470's enrollment target sits among peer trials
388 973rd of 2000 higher than 1,028 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04092010 · 388 participants · NA
Improving Preschool Outcomes by Addressing Maternal Depression in Head Start
- NCT05157880 · 388 participants · NA
Building Resiliency in Dyads of Patients With an ANI Admitted to the Neuro-ICU and Their Informal Caregivers
- NCT05748613 · 388 participants · NA
Anxiety Sensitivity Treatment to Reduce Anxiety in Alzheimer's
- NCT06374277 · 388 participants · NA
Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI